{
  "trial_id": "NCT02700022",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "\u226518 y/o (no upper age limit)",
      "label": "met"
    },
    {
      "criterion": "ECOG PS \u22642",
      "label": "met"
    },
    {
      "criterion": "Disease - Histologically or cytologically documented newly diagnosed (stages II, III or IV) Myc-positive DLBCL, transformed follicular lymphoma, or high-grade unclassifiable with features intermediate between DLBCL and Burkitt lymphoma",
      "label": "met"
    },
    {
      "criterion": "Myc Positive lymphoma is defined by: Positive for Myc gene rearrangement by fluorescence in-situ hybridization (FISH) involving various breakpoints (e.g. 8-14, 8-22 and 2-8) AND concurrent gene rearrangements in bcl-2 and/or bcl-6 by FISH OR Myc and Bcl-2 overexpression defined by > 40% Myc and > 70% Bcl-2 expression by IHC.",
      "label": "met"
    },
    {
      "criterion": "Positive for CD20 via immunophenotyping",
      "label": "met"
    },
    {
      "criterion": "Prior Treatment: Previously untreated or who received a maximum of one cycle of combination chemotherapy (i.e. R-CHOP, R-EPOCH, or R-hyperCVAD) within 4 weeks of study entry except patients who require dose reduction after the first cycle of off-study R-EPOCH.",
      "label": "met"
    },
    {
      "criterion": "Measurable disease as assessed by 2 dimensional measurements by CT (\u2265 1.5 cm).",
      "label": "met"
    },
    {
      "criterion": "Adequate organ function as demonstrated by: Bone marrow function (without platelet transfusion or myeloid growth factor support within two weeks of screening) as demonstrated by:",
      "label": "met"
    },
    {
      "criterion": "Hemoglobin \u2265 8 g/dL",
      "label": "met"
    },
    {
      "criterion": "Absolute neutrophil count (ANC) \u2265 1,000 cells/mm3",
      "label": "met"
    },
    {
      "criterion": "Platelet count \u226575,000/mm3",
      "label": "met"
    },
    {
      "criterion": "And hepatic and renal function as demonstrated by: Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) \u22642.5 x upper limit of normal (ULN); ALT and AST up to 5 x ULN if liver metastases present",
      "label": "met"
    },
    {
      "criterion": "Total serum bilirubin \u22641.5 x ULN",
      "label": "met"
    },
    {
      "criterion": "Serum creatinine \u22641.5 x ULN or CrCl of \u2265 30 mL/minute based on Cockcroft-Gault formula",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "CNS involvement of DLBCL",
      "label": "triggers"
    },
    {
      "criterion": "Major surgery within 4 weeks prior to entry",
      "label": "unknown"
    },
    {
      "criterion": "Receiving any other concurrent cytotoxic, biologic agent(s) or investigational agent ; NOTE: Concurrent intrathecal chemotherapy for CNS prophylaxis allowed per institutional standards",
      "label": "triggers"
    }
  ],
  "notes": "Patient is a 44 year old female with PMH of PCOS, Obesity, HTN who presented with symptoms of cholecystitis and was found incidentally to have a large pericardial effusion. A pericardiocentesis was performed and the fluid analysis was consistent with Burkitt's lymphoma.",
  "_meta": {
    "topic_id": "4",
    "trial_id": "NCT02700022",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}